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Background: Mesenchymal stem cells (MSCs) are increasingly considered to be used as biological immunosuppressants
in hematopoietic stem cell transplantation (HSCT). In the early reconstitution phase following HSCT, natural killer (NK) cells
represent the major lymphocyte population in peripheral blood and display graft-vs-leukemia (GvL) effects. The
functional interactions between NK cells and MSCs have the potential to influence the leukemia relapse rate after
HSCT. Until date, MSC-NK cell interaction studies are largely focussed on bone marrow derived (BM)-MSCs.
Umbilical cord derived (UC)-MSCs might be an alternative source of therapeutic MSCs. Thus, we studied the
interaction of UC-MSCs with unstimulated allogeneic NK cells.
Results: UC-MSCs could potently suppress NK cell cytotoxicity in overnight cultures via soluble factors. The main
soluble immunosuppressant was identified as prostaglandin (PG)-E2. Maximal PGE2 release involved IL-1β priming
of MSCs after close contact between the NK cells and UC-MSCs. Interestingly, blocking gamma-secretase activation
alleviated the immunosuppression by controlling PGE2 production. IL-1 receptor activation and subsequent
downstream signalling events were found to require gamma-secretase activity.
Conclusion: Although the role of PGE2 in NK cell-MSC has been reported, the requirement of cell-cell contact for
PGE2 induced immunosuppression remained unexplained. Our findings shed light on this puzzling observation
and identify new players in the NK cell-MSC crosstalk.
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Mesenchymal stem cells (MSCs) are multipotent precur-
sor cells that have the ability to differentiate mainly along
chondrogenic, adipogenic and osteogenic lineages [1]. Al-
though MSCs were originally isolated from bone marrow,
it is now known that MSCs can be derived from various
post-natal tissues like placenta, umbilical cord and cord
blood, as well as adult tissues like tooth pulp, skin, adipose
tissue, the nervous system and kidney [2,3]. MSCs can be
defined as a heterogenous population of plastic-adherent
cells with fibroblast-like morphology that express certain* Correspondence: jacobs.roland@mh-hannover.de
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article, unless otherwise stated.markers like CD90, CD73, and CD105, but are negative
for surface markers of the hematopoietic lineage such as
CD14, CD19, CD34, CD45, and HLA-DR [4].
MSCs have been reported to mediate profound im-
munosuppressive effects on T -, B -, NK cells, and den-
dritic cells [5]. MSCs are referred to as immunoprivileged
as they possess a hypo-immunogenic profile due to lack of
MHC class II molecules and classical co-stimulatory li-
gands as well as very low expression of MHC class I [6].
This immunoregulatory capacity together with their inher-
ent non-immunogenicity makes them promising candidates
for the use as biological immunosuppressants or tolerance
inducers in alloimmune diseases like steroid resistant acute
graft-versus-host-disease (GvHD) [7], organ transplantation
or implantation of engineered tissues.tral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
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of innate immunity due to their cytolytic activity against
tumour cells and virus infected cells as well as by their
ability to secrete various cytokines and chemokines [8].
NK cells comprise the main lymphocyte population in
the early reconstitution phase after hematopoietic stem
cell transplantation (HSCT) and mediate significant
graft-vs-leukemia (GvL) effect [9,10] while MSCs are
being increasingly used to treat GvHD following HSCT
[11]. In therapeutic settings, the interaction of NK cells
with MSCs might affect NK cell functions and the
transplantation outcome. Clinical intervention to pre-
vent any such adverse outcome of NK-MSC interaction
requires precise understanding of the molecular mecha-
nisms utilised by MSCs to suppress NK cells. Some
work has been done to characterise the interaction of
bone marrow derived MSCs (BM-MSCs) with NK cells
[12-14]. However, interaction of umbilical cord derived
MSCs (UC-MSCs) with NK cells is largely unexplored. Al-
though effective, BM-MSCs are inherently afflicted with
the issue of low proliferative potential and only very low
numbers of MSCs can be isolated from bone marrow via
painful invasive procedures. There is a constant hunt for
better sources of MSCs for future clinical cell-based ther-
apies. UC-MSCs have emerged as an ideal candidate
owing to their non-invasive isolation procedure, superior
proliferative potential and simple accessibility in large
quantities [15]. Thus we chose to study UC-MSC–NK cell
functional interplay.
This project was aimed at elucidating the underlying
molecular mechanisms of UC-MSC mediated immune-
modulatory effects on freshly isolated, human NK cells
without the presence of any NK cell activating cytokine
like IL-15 or IL-2 in the co-culture system. Previous
work on BM-MSC-induced suppression of NK cell
functions implicated soluble factors like indoleamine
2,3-dioxygenase (IDO), transforming growth factor
(TGF)-β and prostaglandin (PG)-E2. PGE2 is the sol-
uble immunosuppressant which is common to all re-
ports till date [12,13,16]. However, the suppression of
NK activation through PGE2 was reported to be contact
dependent [13]. This indicated that the inhibition via
PGE2 involved a more complex pathway that is yet to
be understood. We also found that the UC-MSCs sup-
pressed NK cell cytotoxicity mainly via PGE2 but the
maximal release of PGE2 occurred only in contact cul-
tures. Small amounts of interleukin (IL)-1β present in
NK cells preparations were found to act on UC-MSCs
to stimulate maximal PGE2 production. Additionally,
we show that efficient IL-1 receptor (IL-1R) activation
in MSCs require gamma-secretase enzyme activity.
These findings further corroborate the recent reports
on the identification of IL-1R as a novel gamma-
secretase substrate [17].Results
Phenotypic analysis and differentiation potential of
UC-MSCs
The surface antigen expression patterns on the UC-
MSCs were analysed using flow cytometry (Figure 1).
CD73, CD90, and CD105 were highly expressed. MSCs
lacked the expression of CD14, CD19, CD45, and HLA-
DR on their cell surface. There was a very faint expression
of CD34. The ability of the UC-MSCs to undergo chon-
drogenic, adipogenic and osteogenic differentiation was
determined as described before (data not shown) [3].
Hence, the UC-MSCs fulfilled all the criteria recom-
mended by the International Society for Cellular Therapy
for identifying MSC [4].
Effect of UC-MSCs on NK cell function and phenotype
To examine the effect of MSCs on NK cells, freshly iso-
lated, unstimulated NK cells were incubated with MSCs
in direct contact at ratio 5:1, 10:1, and 20:1 for 16 hours.
Following the co-culture, NK cells were harvested and
exposed to K652 target cells to trigger NK cell degranu-
lation. Surface expression of CD107a was analysed as a
marker for degranulation. We found that NK cells pre-
cultured with MSCs had significantly reduced degranu-
lation capacity compared to NK cells cultured alone
(Figure 2A). There was no significant difference in the
suppression induced by different ratios of MSC during
co-culture (Figure 2A). For all subsequent experiments,
the NK: MSC ratio of 10: 1 was used. To confirm that
the freshly isolated NK cells did not kill the MSCs dur-
ing the co-culture, we performed chromium release
assay with MSCs as target cells. We observed that the
NK cells could efficiently lyse K562 cells but not the
MSCs (Additional file 1: Figure S1). IL-15 pre-activated
NK cells were better at killing the MSCs but the lysis
was still less when compared to K562 (Additional file 1:
Figure S1).
Following HSCT, CD56bright NK cell subset is the major
NK cell population in peripheral blood [9,18,19]. Our
study aims to understand the fate of NK cells following
MSC co-transfusion in HSCT settings. Therefore, we also
specifically analysed the effect of MSCs on CD56bright NK
cells. We found that co-culturing with MSCs could signifi-
cantly suppress K562-induced degranulation (Figure 2B)
as well as IL-12 + IL-18 stimulated interferon-γ produc-
tion by CD56bright NK cells (Additional file 2: Figure S2).
The observed suppression of NK cell cytotoxicity could
have resulted from an altered expression of NK cells sur-
face receptors which are crucial to NK cell activation.
Using flow cytometry-based analysis, we looked for
phenotypic changes on NK cells pre-cultured with MSCs
compared to NK cells cultured alone. The panel of NK cell
receptors analysed included CD16, CD27, CD62L, CD69,
CD94, CD158, CD244, CD247, CD335, CD336, CD337,
Figure 1 Phenotype of UC-MSCs. UC-MSCs were detached using accutase and stained with antibodies against CD14, CD19, CD34, CD45, CD73,
CD90, CD105, and HLA-DR (shaded histograms) or isotype control antibodies (filled histograms).
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all receptors tested was unaffected (Additional file 3:
Figure S3) by MSCs, except for NKG2D. UC-MSCs sig-
nificantly downregulated NKG2D receptor expression on
both CD56dim and CD56bright NK cells (Figure 2C,D). We
also examined if perforin or granzyme contents of NK
cells were altered upon co-culturing with MSCs. Intracel-
lular staining demonstrated that perforin and granzyme
contents of NK cells cultured with MSCs were comparable
to NK cells cultured alone (Figure 2E,F,G,H, Additional
file 4: Figure S4).
Mechanism of MSC-mediated suppression of NK cell
cytotoxic functions
To verify the role of soluble factor(s) in MSC-induced
suppression of NK cell cytotoxicity, we collected condi-
tioned media (cm) from MSC cultures (MSC cm) and
MSC-NK cell co-cultures (NK-MSC cm). NK cells were
cultured in normal media or MSC cm or NK-MSC cm
overnight and subsequently incubated with K562 target
cells. Both MSC cm and NK-MSC cm were found to in-
hibit NK cell degranulation. However, NK-MSC cm was
able to suppress NK cell degranulation more effectively
than MSC cm (Figure 3A). These results were further
corroborated by chromium release assays in which NK
cells were cultured in normal media or MSC cm or NK-
MSC cm overnight and subsequently incubated with
radioactive chromium (51Cr) labelled K562 target cells.
The extent of K562 lysis was determined by the 51Cr re-
leased into the culture supernatants. MSC cm sup-
pressed NK cell cytotoxicity but to a significantly lowerdegree than NK-MSC cm (Figure 3B). This suggested
that the suppressing soluble factor was present in lower
amounts in MSC cm. Only when MSCs and NK cells
came into contact, the soluble factor was released in lar-
ger amounts and resulted in enhanced suppression as
seen with NK-MSC cm. MSC cm reduced cytotoxicity
significantly, but not maximally, while the transwell
system had no significant effect (Additional file 5:
Figure S5). It has been reported by other groups [12,13]
that indoleamine-2,3-dioxygenase (IDO) and cyclooxygen-
ase (COX)-2 or transforming growth factor beta (TGF)-β
produced by MSCs are responsible for suppression of
NK cell cytotoxicity. We investigated if soluble end-
products like prostaglandin (PG)-E2 or kynurenine (from
COX-2 or IDO respectively) or TGF-β played any role in
our system. Antibody mediated blocking of TGF-β and
pharmacological inhibition of IDO by 1-MT did not result
in increased degranulation (Additional file 6: Figure S6A,B).
We found constitutive expression of COX-2 in UC-MSCs.
Overnight co-culture of MSCs with NK cells resulted in
significant upregulation of COX-2 (Figure 3C) in MSCs.
However, no expression of COX-2 was observed in the co-
cultured NK cells (Additional file 7: Figure S7). Blocking of
COX-2 by a small-molecule inhibitor (NS-398) could sig-
nificantly restore NK cell degranulation (Figure 3D). This
indicated that PGE2 could be the major immunosuppres-
sive factor released by MSCs inhibiting NK cell cytotoxicity.
UC-MSCs, when cultured overnight in NK cell cm (NK
cm), also upregulated COX-2 (data not shown). This indi-
cated that some secretory molecules coming from NK cells
could trigger COX-2 upregulation in UC-MSCs. We found
Figure 2 Suppression of NK cell cytotoxicity by UC-MSCs. A: NK cells were cultured alone or with MSCs at NK cell: MSC ratio of 5:1, 10:1, and
20:1. Following overnight co-culture, CD107a degranulation assay was performed with K562 target cells. The bar graphs represent the percentage
of CD107a+ NK cells (n = 5) B: NK cells were cultured without MSCs or with MSCs at NK cell: MSC ratio of 10:1. CD107a degranulation assay was
performed with K562 target cells (n = 5). Following overnight co-culture, CD107a expression on CD56 bright NK cells was analysed. The bar graphs
represent the percentage of CD107a+ cells (n = 9). C, D: NK cells were cultured overnight with or without MSCs. NKG2D expression on the NK cells was
analysed by flow cytometry. The bar graphs depict the mean fluorescence intensity (MFI) of NKG2D staining on CD56 dim (C; n = 9) and CD56 bright
(D; n = 8) NK cells. E, F, G, H: NK cells were cultured overnight with or without MSCs. Perforin (E; n = 7), granzyme A (F; n = 7), granzyme B (G; n = 5),
and granzyme K (H; n = 7) content of the NK cells was analysed by flow cytometry.
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is to be noted that the freshly isolated NK cells were produ-
cing IL-1β without prior exposure to MSCs. We hypothe-
sized that this IL-1β could be responsible for the observed
COX-2 upregulation in MSCs. To verify our hypothesis, we
added IL-1β neutralising antibody in NK-MSC co-cultures.This resulted in significant inhibition of COX-2 upregula-
tion (Figure 3F).
Role of gamma-secretase in IL-1 signalling
IL-1β is known to act via IL-1 receptor present on target
cells. IL-1 receptor (IL-1R) activity has been recently
Figure 3 Mechanism of MSC-mediated suppression of NK cell degranulation. A: NK cells were cultured in normal medium or in MSC cm or in
NK-MSC cm. CD107a degranulation assay was performed with K562 as target cells. Representative dot plots of the alterations in NK cell degranulation
are shown (n = 3). B: NK cell-mediated cytotoxicity was determined by chromium release assay in different conditioned media (n = 3). C: UC-MSCs were
cultured overnight with or without NK cells. Intracellular staining for COX-2 was performed and analysed by flow cytometry. One representative figure
and bar graphs (n = 5) depicting COX-2 upregulation in UC-MSCs cultured with NK cells in comparison with COX-2 expression in “unprimed” UC-MSCs
is shown. D: NK cells were cultured with or without MSCs or co-cultured in presence of NS-398 or DMSO. CD107a degranulation assay was performed
with K562 target cells. The bars represent the effect of COX-2 inhibition on degranulative capacity of NK cells (n = 5). E: NK cells from four different
donors were cultured for 16 hours and culture supernatants were collected. The bars represent the IL-1β levels measured in the supernatants (n = 4).
F: MSCs were co-cultured with NK cells in presence of IL-1β neutralising antibody or matched isotype antibody. The bars illustrate the effect of IL-1β
blocking on COX-2 expression (n = 4).
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in HEK293T cells as well as mouse embryonic fibroblasts
(MEFS) [17]. We examined if IL-1R signaling in human
UC-MSCs depended on gamma-secretase activity. We
cultured UC-MSCs with varying concentrations of IL-1β
overnight in presence or absence of gamma-secretase in-
hibitor, DAPT. IL-1β was very efficient in upregulating
COX-2 levels. However, the presence of DAPT signifi-
cantly reduced COX-2 upregulation (Figure 4A).
Pharmacological inhibitors can have a wide range of tar-
gets. To eliminate this possibility, we performed small
interfering RNA (siRNA) mediated silencing of gamma-
secretase activity in MSCs. We chose to knock-downPresenilin (PSEN)-1 because it is one of the catalytic sub-
units of gamma-secretase complex [20,21]. siRNA targeting
PSEN-1 or control scrambled (SCR) siRNAs were intro-
duced into the MSCs by electroporation. Knock-down of
PSEN-1 mRNA was analysed after 24 hours by real-time
PCR. PSEN-1 siRNA caused a 75% decrease in PSEN-1
mRNA compared to SCR siRNA (Additional file 8: Figure
S8). In parallel with the assessment of mRNA knock-
down, siRNA-treated MSCs were cultured for 16 hours in
presence or absence of IL-1β. Similar to DAPT-mediated
inhibition, PSEN-1 silencing significantly reduced COX-2
upregulation in response to IL-1β (Figure 4B). Introduc-
tion of PSEN-1 siRNA did not affect the basal COX-2
Figure 4 Effect of gamma-secretase on IL-1 signalling and PGE2 content. A: UC-MSCs were cultured in presence of different doses of IL-1β
stimulation with or without DAPT (gamma-secretase inhibitor). UC-MSCs were detached using accutase and stained to analyse intracellular COX-2
expression (n = 5). B: Gamma-secretase activity in UC-MSCs was silenced using siRNA targeting a catalytic subunit of gamma-secretase (PSEN-1).
Scrambled siRNA (SCR) was also introduced into UC-MSCs as control. After 24 hours, PSEN-1 or SCR siRNA treated MSCs were stimulated with
IL-1β overnight. UC-MSCs were detached using accutase and stained to compare intracellular COX-2 expression with or without IL-1β stimulation
(n = 3). C: UC-MSCs were stimulated with IL-1β for 40 minutes, with or without 2.5 hours pre-treatment with DAPT. MSCs were detached using
accutase, immediately fixed, permeabilised and stained to analyse intracellular pJNK levels (n = 4). D: NK cells were cultured with or without MSCs
or co-cultured in presence of 6 μM DAPT, 10 μM DAPT or DMSO. CD107a degranulation assay was performed with K562 target cells. The bars
represent the effect of gamma-secretase inhibition on degranulative capacity of NK cells (n = 5). E: NK cells were cultured in NK cell conditioned
media (NK cm) or in NK-MSC conditioned media (NK-MSC cm) or NK-MSC conditioned media where they were co-cultured in presence of 10 μM
DAPT or DMSO (NK-MSC-10 μM DAPT cm or NK-MSC-DMSO cm respectively). Chromium release assay was performed with K562 target cells
(n = 3). F: PGE2 concentration in MSC cm, NK-MSC cm or NK-MSC-10 μM DAPT cm as determined by competitive ELISA (n = 3).
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ment of gamma-secretase in IL-1R signalling. Next, we
tested if this effect of gamma-secretase blocking stemmed
from impairment of IL-1R downstream signalling. We
pre-treated MSCs with DAPT for 2.5 hours followed by
IL-1β stimulation for 40 minutes. The DAPT pre-treated
MSCs showed significant impairment in their ability to
phosphorylate c-Jun N-terminal kinases (JNK) as mirrored
in reduced phosphorylation of JNK following stimulation
by IL-1β (Figure 4C). We further investigated if gamma-
secretase influenced IL-1R signalling in our culture-
setting. Pharmacological inhibition of gamma-secretaseactivity in NK-MSC co-cultures resulted in a restoration
of NK cell degranulative capacity (Figure 4D). To establish
that gamma-secretase blocking indeed affected the release
of soluble suppressants, we performed the following ex-
periment. Cell-free supernatants were collected from the
NK-MSC co-cultures conducted in presence of DAPT or
DMSO. They have been referred to as MSC-NK-DAPT
conditioned medium (NK-MSC-DAPT cm) and MSC-NK-
DMSO conditioned medium (NK-MSC-DMSO cm), re-
spectively. NK cm and NK-MSC cm were also collected as
controls. NK cells were cultured in these conditioned
media followed by chromium release assay. NK-MSC cm
Chatterjee et al. Cell Communication and Signaling 2014, 12:63 Page 7 of 11
http://www.biosignaling.com/content/12/1/63caused a significant decline in lytic potential of NK cells.
The cell-free co-culture supernatant generated in presence
of gamma-secretase blocker, DAPT, had non-significant
suppressive capacity. This indicated that NK-MSC-DAPT
cm contained much lower quantity of the suppressant
(Figure 4E). To directly test if the release of PGE2 was
gamma-secretase dependent, we performed ELISA to ana-
lyse the concentration of PGE2 in MSC cm, NK-MSC cm,
and NK-MSC-10 μM DAPT cm. We found that the
amount of PGE2 increased significantly upon NK-MSC
co-culture, but there was no increase in PGE2 if gamma-
secretase activity was blocked (Figure 4F).
Discussion
We observed that UC-MSCs were able to suppress NK
cell effector functions in 16 hours of co-culture which is
much shorter than the effective co-culture period de-
scribed by other groups [12,13]. This discrepancy could
be possibly explained by different culture conditions.
The impairment of NK cell cytotoxicity towards K562
cells probably resulted from reduced degranulation.
Interestingly, following co-culture with UC-MSCs, there
was preferential downregulation of NKG2D on NK cells
while no change was observed in the other activating re-
ceptors examined. NKG2D is one of the most prominent
activating receptor on the NK cells [22]. The downregu-
lation of NKG2D could be partially responsible for re-
duced NK cells degranulation towards K562 targets
because this cell line expresses NKG2D activating ligand
[23]. To understand if soluble factors have any role in
the diminution of NK cell cytotoxicity, we compared
cell-free supernatants from MSC cultures and NK-MSC
contact cultures for their NK cells suppressive ability. It
was evident from our experiments that soluble factors
present in the media were responsible for the observed
immunosuppression. NK-MSC cm was significantly su-
perior to MSC cm in suppressing cytotoxic potential of
NK cells indicating a need for a direct contact between
the UC-MSCs and NK cells, for the maximal release of
the cytotoxicity suppressant.
Soluble factors like TGF-β, kynurenine and PGE2 re-
leased by enzymatic action of COX-2 have been reported
to be involved in inhibition of immune cell functions by
BM-MSCs [12,13,24]. In our assays, antibody-mediated
blocking of TGF-β and pharmacological inhibition of
IDO via 1-methyl-tryptophan (MT) did not result in any
restoration of the degranulative potential of NK cells.
These differences could result from the use of unstimu-
lated freshly isolated NK cells in our experiments. It is
known that IDO is induced by IFN-γ in MSC [25], and
freshly isolated NK cells did not produce considerable
amount of IFN-γ (data not shown). We found that COX-2
was constitutively expressed in UC-MSCs. Blocking COX-2
resulted in significant restoration of NK cell degranulationsuggesting that the soluble cytotoxicity suppressant is
PGE2. IL-1β released by NK cells was measured to be in
the range of 70-200 pg/ml. In a murine model of ulcerative
colitis, IL-1β pre-treated MSCs were found to exhibit sig-
nificantly higher therapeutic efficacy than untreated MSCs
[26]. IL-1β is known to be a potent inducer of COX-2.
Hence we neutralised IL-1β in our MSC-NK cell co-
cultures and observed that blocking IL-1β indeed resulted
in a decrease in COX-2 upregulation.
The induction of COX-2 is dependent on IL-1β release
from NK cells. Hence, IL-1β produced by NK cells in trans-
well co-cultures should also induce COX-2 and PGE2 pro-
duction. However, no suppression was observed in
transwell co-cultures. This can possibly be explained by the
low levels of IL-1β produced by NK cells, making direct
cell-cell contact a pre-requisite for attaining effective con-
centrations for bioactivity. In transwell co-cultures, the low
IL-1β concentrations appear insufficient to upregulate
COX-2 in MSCs. It is important to note that our co-culture
duration is just 16 hours. In conditioned media collected
from NK cultures (NK cm) after 16 hours, IL-1β has prob-
ably reached effective concentrations as implicated by
COX-2 upregulation in MSCs exposed to NK cm.
Previous work has demonstrated that gamma-secretase
acts on IL-1R and controls the downstream signalling fol-
lowing receptor activation by ligand binding [17]. We hy-
pothesized that the IL-1R signalling in MSCs could also
be gamma-secretase dependent. We inhibited gamma-
secretase enzyme activity using pharmacological inhibitors
or siRNA-mediated knockdown. We found that the inhib-
ition of gamma-secretase significantly reduced COX-2
upregulation in MSCs in response to IL-1R activation by
IL-1β. We could also demonstrate that gamma-secretase
inhibition also affected JNK phosphorylation down-stream
of IL-1R activation. Therefore, we could demonstrate that
IL-1R signalling in MSCs was dependent on gamma-
secretase activity. This dependence was also mirrored in
the drastic mitigation of PGE2 release under conditions of
gamma-secretase inhibition. Finally, pharmacological inhib-
ition of gamma-secretase during NK cell-MSC co-cultures
showed significant restoration of NK cell degranulation.
Conclusion
Use of MSCs for cell therapy is on the rise, and BM-MSCs
have been shown to be advantageous for the treatment
and prevention of GvHD as well as facilitation of engraft-
ment following HSCT in several clinical trials [27]. The
mechanistic insights obtained from in-vitro studies indi-
cate that the anti-inflammatory effects of MSCs, that
ameliorate complications following HSCT, stem from sup-
pression of aberrant T-cell proliferation [25]. Following
HSCT, the first lymphocyte population to reconstitute are
NK cells, which contribute to improved engraftment, re-
duced rates of leukemia relapse [28] and decreased GvHD.
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also likely to suppress NK cell functions, thereby eliminat-
ing their beneficial effects.
We found that UC-MSCs indeed suppress NK cell
cytotoxicity in overnight contact cultures. The suppres-
sion is mediated by the soluble suppressant PGE2. How-
ever, the maximal release of PGE2 required a cross-talk
between NK cells and MSCs involving IL-1β/IL-1R signal-
ling. The low IL-1β levels are probably more effective
within the immunological synapse formed in contact cul-
tures. This could explain the contact dependence of ob-
served suppression. We also show that the IL-1R signalling
is dependent on gamma-secretase enzyme activity. Finally,
pharmacological inhibition of gamma-secretase significantly
alleviated MSC-induced suppression. We need to further
investigate if these immunosuppressive mechanisms also
apply to MSCs derived from other sources. Identification of
common molecular pathways utilised by MSCs, irrespective
of the source, could have significant clinical implications,
especially in case of HSCT.
Materials and methods
Isolation and culture of UC-MSCs
This study was approved on 26th February, 2009 by the
Institutional Review Board (Project No. 3037) in an ex-
tended permission # 443. After obtaining written con-
sent, MSCs were isolated from at least four different
human umbilical cords obtained from full-term infants
(38-40 weeks) by explant culture, expanded and cryopre-
served until the start of the experiment as described else-
where [3,29]. αMEM supplemented with 10% human
serum and 50μg/ml streptomycin, 50U/ml penicillin,
1mM glutamine and 0.5mM sodium pyruvate (Biochrom,
Berlin, Germany) was used to culture UC-MSCs for all
subsequent experiments.
Isolation of peripheral blood mononuclear cells (PBMC)
and NK cells
Heparinised blood samples were obtained from healthy
consenting donors and diluted with an equal volume of
phosphate buffered saline (PBS). PBMC were separated by
centrifugation over a ficoll-hypaque gradient and stained
with anti-CD56 and CD3 antibodies. NK cells were sorted
using MoFlo Cell Sorter (Beckman Coulter) at the MHH
sorting facility. NK cells were defined as CD56+CD3−
lymphocytes.
Monoclonal antibodies (mAbs)
The anti-human mAbs have been used: CD3 PE (from
Beckman Coulter), CD3 PerCP, CD11b PE, CD14 APC,
CD56 PE, CD56 APC, CD73 PE, CD107a FITC, Gran-
zyme A FITC, Perforin FITC, pJNK PE (from BD Biosci-
ences), HLA-DR FITC (Dako), CD44 FITC, CD105 FITC,
Granzyme B PE, Granzyme K Alexa647 (Immunotools),CD90 APC, COX2 FITC (Cayman chemicals). Each flow
cytometric analysis was controlled with isotype-matched
mAbs. All flow cytometry-based experiments were per-
formed on FACS Calibur using Cell-Quest Pro Software.
Offline data analysis was done on Summit 5.1 software.Cell culture
UC-MSCs were seeded in 24- or 48-well plates and allowed
to adhere. After 24 hours, freshly isolated, FACS-sorted NK
cells from unrelated donors were added at a MSC:NK-ratio
of 1:10. Following 16 hours of co-culture, the NK cells were
removed from the adherent MSCs by pipetting for pheno-
typing or were tested for cytokine producing ability by
intracellular staining or for cytotoxic potential against K562
leukemic cells using CD107a degranulation or chromium
release assay. NK cells cultured without MSCs were used as
controls. Cell-free supernatants from the NK-MSC co-
cultures or MSC cultures were frozen for further analysis
as MSC-NK-conditioned medium (NK-MSC cm) or MSC
conditioned media (MSC cm), respectively. For determin-
ing the influence of conditioned media, NK cells from the
unrelated donors were cultured for 16 hours in the cell-free
supernatants generated as mentioned above. To determine
the role of gamma-secretase activation, N-[N-(3,5-Difluoro-
phenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester (DAPT)
(Sigma-Aldrich, Germany), a gamma-secretase inhibitor,
was added to the co-cultures at 6 μM or 10 μM concentra-
tions. DMSO was used as vehicle control. 5 μM NS-398
was added to the co-cultures to block the action of cycloox-
ygenase (COX)-2. IL-1β neutralising antibody or the
matched isotype control antibody was added to the co-
cultures at a concentration of 10 ng/ml.Detection of intracellular proteins
For detection of perforins and granzymes, after surface
staining, cells were fixed with 4% paraformaldehyde
(Merck) for 10 min. Subsequently, the cells were perfo-
rated in 0.1% saponin buffer (PBS supplemented with 0.1%
Saponin (Riedel-de-Haën) and 0.01M HEPES (Roth) and
fluorochrome-tagged monoclonal antibodies (mAbs) were
added. After 30 minutes of incubation and three washes,
cells were analysed by flow cytometry.
For detection of COX-2, the MSCs were detached by
Accutase (Life technologies) treatment at 37°C for 5 min
and fixed with 4% paraformaldehyde followed by 30 minute
incubation with anti-COX-2 mAb in saponin buffer. The
cells were then washed and analysed by flow cytometry.
For detection of pJNK, MSCs were stimulated with IL-
1β for 40 minutes and washed once with PBS. Detach-
ment of MSCs using Accutase was immediately followed
by fixation using 1X BD Lyse/Fix Buffer. The permeabil-
isation and intracellular staining for pJNK was per-
formed according to manufacturer’s protocol.
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NK cells cultured with or without MSCs were incubated
with K562 target cells in presence of anti-CD107a mAb
at an Effector:Target (E:T) ratio of 10:1. Monensin (BD
Biosciences) was added after 1 hour at a final concentra-
tion of 6 μg/ml and the incubation was continued for 3
hours. The cells were then analysed for the surface-
expression of CD107a by flow cytometry.
Cytotoxicity assay against K562 target cells
Cytotoxicity of NK cells, cultured under different condi-
tions e.g in presence/absence of MSCs or in the pres-
ence/absence of conditioned media, was determined by
4 hour chromium release assay against K562 target cells
following the protocol as described elsewhere [30]. Briefly,
K562 cells were labelled with radioactive 51Cr by incubat-
ing the cells with 3 MBq Na51CrO4 for 1h at 37°C. The
cells were washed twice and plated in triplicates in V-bottom
96-well plates. Effector: Target ratios of 20:1, 10:1, 5:1 and
2.5:1 were used. NK cell mediated lysis of targets results in
the release of 51Cr into the supernatant. Following the 4
hour incubation, the plates were centrifuged. 25 μl cell-free
supernatant was collected from each well, and the 51Cr
release was measured by a gamma counter. Lytic units
(LU20/10
7 cells) of the assays were calculated according to
the methods established by Bryant et al. [31].
Cytokine bead array
The amount of IL-1β present in the culture supernatants
of NK cells was measured using the cytometric bead array
kit (BD Biosciences) in combination with human IL-1β
Flex set according to the manufacturer’s protocol. Briefly,
fluorescently labelled beads (bead position B4) were mixed
with known standards or test samples followed by incuba-
tion with PE-conjugated detection antibodies. The samples
were washed, measured on FACS Canto II and analysed
using the BD CBA analysis software.
Prostaglandin(PG)-E2 ELISA
PGE2 was measured in culture supernatants by com-
petitive enzyme-linked immunosorbent assay (ELISA)
technique using a commercially available ELISA kit
(Enzo Life Sciences), according to the manufacturer’s
protocol. Concentrations were calculated by compari-
son with known PGE2 standards using a 5 parameter lo-
gistic curve fitting program.
siRNA transfections
The following small interfering RNA (siRNA) were
obtained from Dharmacon, Thermo Scientific: ON-
TARGETplus Non-targeting Control Pool (D-001810-
10-05), ON-TARGETplus PSEN1; Set of 4 (LQ-
004998-00-0002). The four individual PSEN1 targeting
siRNAs were mixed (i.e. 37.5 pmol each) before use.Transfection with siRNAs was performed using the
Neon transfection system (Invitrogen) at 1350 V, 10 ms,
4 pulses; according to the manufacturer’s instructions.
siRNAs were microporated at the concentration of 150
pmol into 8×104 cells.Real-time PCR
Total RNA was isolated from siRNA-treated UC-MSCs
using RNAeasy Micro Kit (Qiagen), according to manufac-
turer’s protocol. cDNA was prepared using a commercially
available reverse transcription kit (Applied Biosystems; Cat.
No: 4368814). Expression of PSEN-1 mRNA relative to
β-actin was analyzed using semi-quantitative PCR. All
experiments were performed in triplicates. Fold change
in PSEN-1 mRNA expression was calculated using the
2-ΔΔCT method. The following primers were used: PSEN-1
primer pair (SantaCruz Biotechnology, Inc.; Cat. No:
sc-36312-PR) and β-actin quantitect primers (Qiagen.; Cat.
No: QT00095431).Statistical analyses
Paired two-tailed t-tests or ANOVA with Bonferroni
post-test were performed using GRAPHPAD PRISM
V5.00 Software. Levels of significance are shown as p-
values (* p < 0.05, ** p < 0.01, *** p < 0.001). Bar graphs
represent mean +/- standard deviation (SD).Additional files
Additional file 1: Figure S1. Specific lysis of UC-MSCs by NK cells.
MSCs or K562 (control) were used as target (T) cells. Freshly isolated,
unstimulated NK cells or IL-15-preactivated NK cells were used as effector
cells. When MSCs were used as targets, MSCs were seeded in flat-bottom
96 well plates and cultured overnight to obtain adherent MSCs, prior to
addition of NK cells. Effector (E) cells were subsequently added to the
targets and chromium release assay was performed (n = 3).
Additional file 2: Figure S2. Effect of UC-MSCs on IFN-γ production
by CD56bright NK cells. NK cells were cultured with or without MSCs.
The NK cells were harvested and stimulated with IL-12 and IL-18.
Brefeldin A was added after 1 hour of culture. At the end of 4 hours of
stimulation, the cells were intracellularly stained for IFN-γ, and analysed
by flow cytometry (n = 6).
Additional file 3: Figure S3. Effect of UC-MSCs on NK cell
phenotype. NK cells were cultured with or without MSCs for 16 hours. The
cells were surface stained and the expression of the indicated receptors was
analysed by FACS. All experiments were repeated at least three times.
Additional file 4: Figure S4. Effect of MSCs on perforin and
granzyme content of NK cells. NK cells were cultured overnight with or
without MSCs. Perforin (n = 7), granzyme A (n = 7), granzyme B (n = 5),
and granzyme K (n = 7) content of the NK cells was analysed by flow
cytometry. Representative dot plots, depicting the staining for perforin
(A) and granzymes (B, C, D), are shown.
Additional file 5: Figure S5. Impact of UC-MSCs on NK cell
cytotoxicity in transwell settings. NK cells were cultured without MSCs
or with MSCs separated by transwell inserts. MSCs were seeded in the
lower well before NK cells were added in transwell inserts. Chromium
release assay was then performed to assess the cytotoxic potential of the
NK cells using K562 as target cells.
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UC-MSC mediated suppression. A: NK cells were cultured overnight
with or without MSCs or with MSCs in presence of TGF-β blocking
antibody. The NK cells were harvested and CD107a degranulation assay
was performed with K562 as target cells (n = 4). B: NK cells were cultured
overnight with or without MSCs or with MSCs in presence of 1-MT. The
NK cells were harvested and CD107a degranulation assay was performed
with K562 as target cells (n = 4).
Additional file 7: Figure S7. Lack of COX-2 expression in NK cells
cultured with MSCs. NK cells cultured with MSCs were harvested. The
cells were surface stained, followed by intracellular staining with
anti-COX-2 antibody or matching isotype control antibody. Representative
dot plots, depicting the lack of COX-2 expression in NK cells, are
shown (n = 4).
Additional file 8: Figure S8. siRNA mediated knock-down of PSEN-1.
siRNA targeting PSEN-1 or scrambled controls (SCR) were introduced into
the UC-MSCs using electroporation. 24 hours later, total RNA was isolated
from siRNA-treated UC-MSCs, and cDNA was prepared. Expression of PSEN-1
mRNA relative to β-actin was analyzed using semi-quantitative PCR. All
experiments were performed in triplicates. The bar-graphs depict the
fold change in PSEN-1 mRNA expression as calculated using the
2-ΔΔCT method (n = 3).
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